EP4379068A1 - Iridoid- oder seco-iridoidderivate und ihre verwendung in einem gerbverfahren - Google Patents

Iridoid- oder seco-iridoidderivate und ihre verwendung in einem gerbverfahren Download PDF

Info

Publication number
EP4379068A1
EP4379068A1 EP22306770.3A EP22306770A EP4379068A1 EP 4379068 A1 EP4379068 A1 EP 4379068A1 EP 22306770 A EP22306770 A EP 22306770A EP 4379068 A1 EP4379068 A1 EP 4379068A1
Authority
EP
European Patent Office
Prior art keywords
aliphatic group
hydrogen
compound
formula
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22306770.3A
Other languages
English (en)
French (fr)
Inventor
Loic FONTAINE
Thomas Lecourt
Alexandra Le Foll
Stéphane MARCOTTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Hermes Sellier SAS
Institut National des Sciences Appliquees de Rouen
Universite de Rouen Normandie
Original Assignee
Centre National de la Recherche Scientifique CNRS
Hermes Sellier SAS
Institut National des Sciences Appliquees de Rouen
Universite de Rouen Normandie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Hermes Sellier SAS, Institut National des Sciences Appliquees de Rouen, Universite de Rouen Normandie filed Critical Centre National de la Recherche Scientifique CNRS
Priority to EP22306770.3A priority Critical patent/EP4379068A1/de
Publication of EP4379068A1 publication Critical patent/EP4379068A1/de
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C14—SKINS; HIDES; PELTS; LEATHER
    • C14C—CHEMICAL TREATMENT OF HIDES, SKINS OR LEATHER, e.g. TANNING, IMPREGNATING, FINISHING; APPARATUS THEREFOR; COMPOSITIONS FOR TANNING
    • C14C3/00—Tanning; Compositions for tanning
    • C14C3/02—Chemical tanning
    • C14C3/08—Chemical tanning by organic agents

Definitions

  • the present invention relates to the field of tanning. More particularly, the present invention relates to particular iridoid or seco-iridoid derivatives, and their use in a tanning process. It also relates to a process for cross-linking collagen using such derivatives.
  • Natural tannins have long been used in processes for tanning skin and stabilizing collagen.
  • Tanning mixtures are mainly composed of polyphenolic tannins, which are divided into two classes: condensed tannins and hydrolysable tannins.
  • the effectiveness of tanning is usually reflected by its ability to stabilize collagen, namely to limit collagen denaturation and impart good resistance to enzymatic hydrolysis.
  • Collagen stabilization can be assessed by measuring the increase in shrinkage temperature, which is correlated to the collagen denaturation temperature.
  • the polyphenolic tannins give rise to a shrinkage temperature around 75-85°C.
  • Other parameters can also be considered for assessing the effectiveness of tanning, such as the mechanical resistance of the hide and its sensory parameters, such as hide filling and suppleness.
  • genipin can be obtained from geniposide which is extracted from the fruit of Gardenia jasminoides or Genipa americana. Genipin allows to stabilize the collagen and to reach shrinkage temperatures of 80°C ( Zhang et al., JALCA, 2011, 106, 121 ). Genipin has also been used in combination with an aluminum-based tanning ( Ding et al., JALCA, 2008, 103, 377 ), which resulted in a soft and full leather having a shrinkage temperature of 92°C. Genipin has also been used to cross-link gelatin ( Taylor et al., JALCA, 2009, 104, 79 ). Genipin is readily available in large quantities due to its use as a food coloring agent.
  • WO2009/065915 describes a tanning method using aglycone derivatives of iridoids and seco-iridoids, different from genipin.
  • Such derivatives can be extracted from olive leaves and are hydrolyzed to give aglycone forms of oleuropein.
  • the mixture obtained by extraction of the leaves in the presence of endogenous enzyme or by the use of acid is not purified and also comprises polyphenolic compounds and compounds derived from hydrolyzed oleuropein, such as (4E)-4-formyl-3-(-1-formyl-2-methoxy-2-oxoethyl)hex-4-enoic acid.
  • iridoids or seco-iridoids which are highly reactive. This high reactivity can cause several limitations, in particular with regard to the stability, storability, and toxicity.
  • Protected forms of such iridoids or seco-iridoids, in particular glycoside forms are usually more stable and less toxic, however they are not active in tanning and cannot be easily activated under mild conditions compatible with tanning.
  • glycosides can only be activated by means of enzymatic hydrolysis, which is expensive, not always reproducible, and not convenient for large-scale processes.
  • iridoid or seco-iridoid compounds with a particular acyclic acetal group.
  • These protected iridoid or seco-iridoid derivatives can advantageously be obtained starting from the corresponding glycoside forms, by successively subjecting the latter to an oxidation and a reduction.
  • This acetal protecting group can be easily removed before and/or during a tanning process, typically using acidic conditions, thereby releasing the active aglycone form.
  • the present invention relates to the use of a compound of formula (I), in a tanning process: wherein:
  • X is a moiety of aucubin, catalpol, harpagide, ajugol, geniposide, loganin, loganic acid, antirrhinoside, linarioside, feretoside, geniposidic acid, gardenoside, apodanthoside, desacetylasperulosidic acid, scandoside, methoxycinnamoyl scandoside methyl ester, demethyloleuropein, ligustroside, ligustrosidic acid, ligustaloside A, ligustaloside B, nuzhenide, horroxyloganin, oleuropein (or equivalently "oleuropeoside”), hydroxyframoside A, hydroxyframoside B, sweroside, swertiamarin, gentiopicroside, amarogentin, or morroniside, preferably geniposide or gentiopicroside.
  • said compound of formula (I) is a compound of formula (1-2): wherein:
  • said compound is represented by the following formula (I-1): wherein:
  • R 2 is a C 1 -C 12 aliphatic group, preferably a C 1 -C 6 alkyl.
  • R 4 is -C(O)-CH 2 -R 5 or -CH(OH)-CH 2 -R 5 ', where R 5 and R 5 ' are each independently a hydrogen atom, -OH, or -O-C(O)-(C 1 -C 12 aliphatic group), preferably a hydrogen atom, -OH or -O-C(O)-(C 1 -C 6 alkyl).
  • R 3 and R 4 form together a chain of formula (II) as defined herein wherein:
  • each of Y 1 , Y 2 , and Y 3 is independently a hydrogen, -C(O)-phenyl, or -C(O)-(C 1 -C 6 alkyl), preferably a hydrogen or -C(O)-CH 3 , more preferably a hydrogen.
  • a use according to the invention is a use for tanning a hide or a skin.
  • a use according to the invention is a use in a method for manufacturing a leather or a leather substitute.
  • a use according to the invention is a use for tanning a collagen-containing material.
  • the present invention also relates to a compound as defined herein per se , with the proviso that said compound is not one of the following compounds:
  • Another object of the present invention is a process for cross-linking collagen in a material comprising a step of contacting said material with a compound as defined herein.
  • Said material may in particular be a hide or a skin.
  • Figures 1 , 2 , 3 and 4 Images of materials obtained after tanning of a collagen powder using compounds of the invention under various tanning conditions.
  • C x -C y in which x and y are integers, as used in the present disclosure, means that the corresponding chemical group comprises from x to y carbon atoms. If, for example, the expression C 1 -C 6 is used, it means that the corresponding chemical group may comprise from 1 to 6 carbon atoms, especially 1, 2, 3, 4, 5 or 6 carbon atoms. If, for example, the expression C 2 -C 5 is used, it means that the corresponding chemical group may comprise from 2 to 5 carbon atoms, especially 2, 3, 4, or 5 carbon atoms.
  • aliphatic refers to a saturated or unsaturated, cyclic or acyclic (preferably acyclic), linear or branched hydrocarbon chain.
  • C 1 -C 12 aliphatic refers to an aliphatic having 1 to 12 carbon atoms.
  • the aliphatic may be an alkyl, an alkenyl, or an alkynyl.
  • alkyl refers to a saturated, linear or branched hydrocarbon chain.
  • C 1 -C 6 alkyl refers to an alkyl having 1 to 6 carbon atoms. Examples of alkyl (or C 1 -C 6 alkyl) include, for instance, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert -butyl, pentyl, or hexyl.
  • alkenyl refers to an unsaturated, linear or branched hydrocarbon chain, having at least one carbon-carbon double bond.
  • C 2 -C 6 alkenyl refers to an alkenyl having 2 to 6 carbon atoms. Examples of alkenyl (or C 2 -C 6 alkenyl) include for instance, ethenyl, propenyl, butenyl, pentenyl, or hexenyl.
  • alkynyl refers to an unsaturated, linear or branched hydrocarbon chain, having at least one carbon-carbon triple bond.
  • C 2 -C 6 alkynyl refers to an alkynyl having 2 to 6 carbon atoms. Examples of alkynyl (or C 2 -C 6 alkynyl) include, for instance, ethynyl, propynyl, butynyl, pentynyl, or hexynyl.
  • alkoxy refers to a -O-(alkyl) group, where alkyl is as defined above.
  • C 1 -C 6 alkoxy refers to an alkoxy having 1 to 6 carbon atoms. Examples of alkoxy (or C 1 -C 6 alkoxy) include, for instance, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert- butoxy, pentoxy, or hexyloxy.
  • aryl refers to a mono- or bi-cyclic aromatic hydrocarbon having from 6 to 12 carbon atoms.
  • aryl includes phenyl, biphenyl, or naphthyl.
  • the aryl is a phenyl.
  • halogen refers to a fluorine atom, a chlorine atom, bromine atom, or iodine atom.
  • the "salts" of the compounds as defined herein include usual salts formed from inorganic or organic acids or bases as well as quaternary ammonium salts. More specific examples of suitable acid salts include hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, perchloric, fumaric, acetic, propionic, succinic, glycolic, formic, lactic, maleic, tartaric, citric, palmoic, malonic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, fumaric, toluenesulfonic, methanesulfonic, naphthalene-2-sulfonic, benzenesulfonic hydroxynaphthoic, hydroiodic, malic, steroic, tannic etc. More specific examples of suitable basic salts include sodium, lithium, potassium, magnesium, aluminum, calcium, zinc salts.
  • the present invention relates to the use of a compound of formula (I), in a tanning process: wherein:
  • each of Y 1 , Y 2 , and Y 3 is independently a hydrogen, -C(O)-phenyl, or -C(O)-(C 1 -C 6 alkyl), preferably a hydrogen or -C(O)-(C 1 -C 6 alkyl), more preferably a hydrogen or -C(O)-CH 3 , even more preferably a hydrogen.
  • a “dihydropyranyl-oxy” moiety can typically be represented as follows (said moiety being optionally substituted at any position):
  • an “iridoid” refers to a compound comprising a dihydropyranyl-oxy moiety, fused with a cyclopentyl, cyclopentenyl, or tetrahydropyranyl moiety. More particularly, the iridoid may comprise one of the following ring structures (each ring structure, including the oxy of the dihydropyranyl-oxy, being optionally substituted at any position):
  • a "seco-iridoid” refers to a compound comprising a dihydropyranyl-oxy moiety substituted by at least two hydrocarbon chains having each independently at least two carbons. More particularly, the seco-iridoid may comprise one of the following ring structures (each ring structure, including the at least two hydrocarbon chains and the oxy of the dihydropyranyl-oxy, being optionally substituted at any position):
  • the iridoids or seco-iridoids are usually in a glycoside form (i.e. the oxy of the dihydropyranyloxy being in the form of a glucosyl group) or aglycone form (i.e. the oxy of the dihydropyranyl-oxy being in the form of a hydroxy group).
  • a "moiety of an iridoid, a seco-iridoid or a derivative thereof' refers to an iridoid, a seco-iridoid or a derivative thereof, deprived of an atom or a group of atoms, while preserving the backbone of said iridoid, seco-iridoid or derivative thereof.
  • a "moiety of an iridoid, a seco-iridoid or a derivative thereof' refers to:
  • a compound of formula (I) typically refers to the corresponding iridoid (or seco-iridoid or derivative thereof) wherein the glucosyl is formally replaced with the following moiety: wherein Y 1 , Y 2 , Y 3 are as defined herein.
  • a compound of formula (I) typically refers to the corresponding iridoid (or seco-iridoid or derivative thereof) wherein the hydroxy is formally replaced with the following moiety: wherein Y 1 , Y 2 , Y 3 are as defined herein.
  • X is a moiety of aucubin, catalpol, harpagide, ajugol, geniposide, loganin, loganic acid, antirrhinoside, linarioside, feretoside, geniposidic acid, gardenoside, apodanthoside, desacetylasperulosidic acid, scandoside, methoxycinnamoyl scandoside methyl ester, demethyloleuropein, ligustroside, ligustrosidic acid, ligustaloside A, ligustaloside B, nuzhenide, horroxyloganin, oleuropein (or equivalently "oleuropeoside”), hydroxyframoside A, hydroxyframoside B, sweroside, swertiamarin, gentiopicroside, amarogentin, and morroniside.
  • X is a moiety of geniposide (or the aglycone form thereof, genipin) or a moiety of gentiopicroside (or the aglycone form thereof).
  • the compound of formula (I) can typically be represented as follows: wherein Y 1 , Y 2 , Y 3 are as defined herein (preferably, hydrogens).
  • the compound of formula (I) can typically be represented as follows: wherein Y 1 , Y 2 , Y 3 are as defined herein (preferably, hydrogens).
  • the compound of formula (I) is a compound of formula (1-2): wherein:
  • a preferred C 1 -C 12 aliphatic group is a C 1 -C 6 alkyl or a C 2 -C 6 alkenyl. It is understood that this applies to C 1 -C 12 aliphatic group as such, but can also apply to any group mentioned above comprising C 1 -C 12 aliphatic group, such as -C(O)O-(C 1 -C 12 aliphatic group).
  • said aliphatic groups are each independently optionally substituted by one or more hydroxy (preferably one or two), aryl (preferably a phenyl) or glycosyl derivative, said aryl being optionally substituted by one or more hydroxy or (C 1 -C 6 )alkoxy. It is understood that this applies to aliphatic group as such, but also applies to any group mentioned above comprising aliphatic group, such as -C(O)O-(C 1 -C 12 aliphatic group).
  • An example of C 2 -C 12 aliphatic group substituted by a hydroxy is -CH2-CH 2 -OH.
  • each of Y 1 , Y 2 , and Y 3 is independently a hydrogen, -C(O)-phenyl, or - C(O)-(C 1 -C 6 alkyl), preferably a hydrogen or -C(O)-(C 1 -C 6 alkyl), more preferably a hydrogen or -C(O)-CH 3 , even more preferably a hydrogen.
  • R 10 is a hydrogen, -C(O)OH, or -C(O)-O-(C 1 -C 6 alkyl), wherein said C 1 -C 6 alkyl is optionally substituted by a phenyl substituted one or two hydroxy.
  • R 11 ' is a hydrogen
  • R 12 ' is a hydrogen
  • R 11 and R 12 form together a chain of formula (II-2) as defined above,
  • R 11 and R 12 form together a chain of formula (II-2), it is preferred that at least two of R 13 , R 14 , R 15 , and R 16 are not hydrogens.
  • R 11 and R 12 form together a chain of formula (II-3) as defined above, wherein each of R 17 , R 18 , and R 19 is independently a hydrogen, -OH, a hydroxy-(C 1 -C 6 alkyl) (such as hydroxymethyl), -C(O)-(C 2 -C 6 alkenyl), said C 2 -C 6 alkenyl being optionally substituted by a phenyl substituted by a methoxy.
  • R 11 and R 12 form together a chain of formula (II-3), it is preferred that R 18 is hydrogen and, R 17 and R 19 are not hydrogens.
  • R 11 and R 12 form together a chain of formula (II-3) as defined above, wherein R 17 and R 18 are hydrogens and R 19 is -CH 2 -O-C(O)-CH 3 .
  • the compound of formula (1-2) may for instance be the following compound: wherein Y 1 , Y 2 , and Y 3 are as defined herein (preferably -C(O)CH 3 ).
  • R 11 and R 12 form together a chain of formula (II-4) as defined above, wherein each of R 20 , R 21 , R 22 , and R 23 , is independently a hydrogen, -OH, -C(O)OH, or a hydroxy-(C 1 -C 12 aliphatic group), preferably hydrogen, -OH, -C(O)OH, or hydroxy(C 1 -C 6 alkyl) such as hydroxymethyl.
  • R 20 and R 21 are hydrogens and, one or both of R 22 and R 23 are not hydrogens.
  • R 11 and R 12 form together a chain of formula (II-5) as defined above, wherein each of R 24 , R 25 , or R 26 is independently a hydrogen, -OH, or a C 1 -C 12 aliphatic group (such as a C 1 -C 6 alkyl, typically a methyl), or a hydroxy-(C 1 -C 12 aliphatic group).
  • R 11 and R 12 form together a chain of formula (II-5), it is preferred that at least two of R 24 , R 25 , or R 26 are not hydrogens.
  • R 10 and R 11 form together a chain of formula (II-6) as defined above.
  • R 12 ' is a hydrogen and R 12 is not a hydrogen (preferably R 12 is a C 2 -C 12 aliphatic group, more preferably a C 2 -C 6 alkenyl such as an ethenyl).
  • the compound of formula (1-2) is such that:
  • a particular glycosyl derivative is represented as follows:
  • a compound as defined herein is represented by the following formula (I-1): wherein:
  • stereoisomer refers to compounds which have identical molecular formulae as identified herein but which differ in the layout of their atoms in space. Stereoisomers which are not mirror images of each other, are designated as “diastereoisomers”, and stereoisomers which are non-superposable mirror images of each other are designated as "enantiomers” or “optical isomers”. “Stereoisomers” refer to racemates, enantiomers and diastereoisomers.
  • the compound of formula (1-1) as defined herein can be a compound of formula (III), a compound of formula (IV), or a mixture thereof: wherein, in formulae (III) and (IV):
  • the compound of formula (1-1) is a compound of formula (III) or a mixture of a compound of formula (III) and a compound of formula (IV). More preferably, a compound as defined herein is a compound of formula (III).
  • each of Y 1 , Y 2 , and Y 3 is independently a hydrogen, -C(O)-phenyl, or -C(O)-(C 1 -C 6 alkyl), preferably a hydrogen or -C(O)-(C 1 -C 6 alkyl), more preferably a hydrogen or -C(O)-CH 3 , even more preferably a hydrogen.
  • R 2 is a hydrogen atom or a C 1 -C 12 aliphatic group. More particularly, R 2 may be a hydrogen atom or a C 1 -C 6 alkyl group.
  • R 2 is a C 1 -C 12 aliphatic group, more preferably a C 1 -C 6 alkyl, such as a methyl.
  • the compound of formula (1-1) is such that:
  • R 4 is -C(O)-CH 2 -R 5 or -CH(OH)-CH 2 -R 5 ', where R 5 and R 5 ' are each independently a hydrogen atom, -OH, or -O-C(O)-(C 1 -C 12 aliphatic group), preferably a hydrogen atom, -OH or -O-C(O)-(C 1 -C 6 alkyl).
  • R 4 is -C(O)-CH 2 -R 5 , where R 5 is as defined herein.
  • R 5 is a hydrogen atom, a C 1 -C 6 alkyl group, -OH, or -O-C(O)-(C 1 -C 6 alkyl group).
  • R 5 is a hydrogen atom or -O-C(O)-(C 1 -C 12 aliphatic group), more preferably a hydrogen atom or -O-C(O)-(C 1 -C 6 alkyl), even more preferably, a hydrogen atom or -O-C(O)-CH 3 .
  • R 4 is -CH(OH)-CH 2 -R 5 ', where R 5 ' is as defined herein.
  • R 5 ' is a hydrogen atom, -OH, or -O-C(O)-(C 1 -C 6 alkyl group), more preferably a hydrogen atom, -OH, or -O-C(O)-CH 3 .
  • the compound of formula (1-1) is such that:
  • R 3 can be -CH 2 -C(O)H and R 4 can be -C(O)-CH 2 -R 5 , where R 5 is a hydrogen atom or -O-C(O)-(C 1 -C 6 alkyl) (such as -O-C(O)-CH 3 ).
  • R 3 can be -CH 2 -CH 2 -OH and R 4 can be -CH(OH)-CH 2 -R 5 ', where R 5 ' is a hydrogen atom, -OH, or -O-C(O)-(C 1 -C 6 alkyl group) (such as -O-C(O)-CH 3 ).
  • the compound of formula (1-1) is such that:
  • R 3 and R 4 form together a chain of formula (II) as defined herein.
  • the compound of formula (1-1) can be represented as follows: wherein Y 1 , Y 2 , Y 3 , R 2 , R 6 , R 7 , R 8 , and R 9 are as defined herein.
  • stereochemistry of the compound of formula (I-II) may be as follow: wherein Y 1 , Y 2 , Y 3 , R 2 , R 6 , R 7 , R 8 , and R 9 are as defined herein.
  • a compound as defined herein is a compound of formula (III-II) or a mixture (in particular, a racemic mixture) of a compound of formula (III-II) and a compound of formula (IV-II). More preferably, a compound as defined herein is a compound of formula (III-II).
  • each stereogenic center that is not defined encompasses both (R) and (S) configurations.
  • R 6 , R 7 , and R 8 are each independently a hydrogen atom, -OH, or - O-C(O)-(C 1 -C 6 alkyl group) and R 9 is a hydrogen atom or -CH 2 -R 9 ', where R 9 ' is a hydrogen atom, -OH, or -O-C(O)-( C 1 -C 6 alkyl group).
  • At least two among R 7 , R 8 , and R 9 are not hydrogen atoms.
  • R 6 is hydrogen
  • R 7 is hydrogen, -OH or -O-C(O)-(C 1 -C 6 alkyl), for instance hydrogen, -OH or -O-C(O)-CH 3 .
  • R 7 is -OH or -O-C(O)-(C 1 -C 12 aliphatic group).
  • R 7 is -OH or -O-C(O)-(C 1 -C 6 alkyl), more preferably -OH or -O-C(O)-CH 3 .
  • R 7 is -O-C(O)-(C 1 -C 12 aliphatic group), for instance -C(O)-CH 3 .
  • R 8 is hydrogen or -OH.
  • R 8 is -OH.
  • R 9 is a hydrogen atom.
  • R 9 is -CH 2 -R 9 '.
  • R 9 ' is a hydrogen atom, -OH, or -O-C(O)-(C 1 -C 6 alkyl), preferably a hydrogen atom, -OH or -O-C(O)-CH 3 .
  • R 9 ' is a hydrogen atom or -O-C(O)-(C 1 -C 12 aliphatic group).
  • R 9 ' is a hydrogen atom or -O-C(O)-(C 1 -C 6 alkyl), more preferably a hydrogen atom or -O-C(O)-CH 3 .
  • R 9 ' is -O-C(O)-(C 1 -C 12 aliphatic group), for instance -C(O)-CH 3 .
  • the compound of formula (1-1) (or of formula (I-II)) is such that R 3 and R 4 form together a chain of formula (II) wherein:
  • the compound of formula (1-1) (or of formula (I-II)) is such that:
  • the compound of formula (1-1) is such that R 3 and R 4 form together a chain of formula (II) (in particular, is a compound of formula (I-II)) wherein:
  • the compound of formula (1-1) (or of formula (I-II)) is such that:
  • the compound of formula (1-1) is chosen among the following compounds: wherein Y 1 , Y 2 , and Y 3 are as defined herein.
  • the compound of formula (1-1) may be one of the following compounds:
  • the compounds as defined herein can be prepared by any suitable technique known to the skilled artisan.
  • the compounds as defined herein can be prepared as detailed in the examples. More specifically, such compounds may be prepared by contacting an iridoid or a seco-iridoid in its glycoside form, successively with sodium metaperiodate followed by sodium borohydride in water. Subsequent classical steps, such as hydroxylation, oxidation, reduction, or acylation can be carried out to functionalize or insert particular substituents on the iridoid or seco-iridoid.
  • the compounds as defined herein are particularly suitable for use in a tanning process, as tanning or pre-tanning agents.
  • a compound as defined herein can be activated, typically by contacting with an acid, such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, trifluoroacetic acid, methanesulfonic acid, benzenesulfonic acid or p -toluenesulfonic acid (preferably hydrochloric acid), before and/during the tanning process.
  • a compound as defined herein may be contacted with said acid at room temperature, preferably for a duration comprised between 30 min and 48 hours.
  • room temperature refers to a temperature comprised between 15 °C and 40 °C, preferably between 20 °C and 30 °C.
  • pre-tanning refers to a particular step of a tanning process, which is a preliminary step where a first tanning agent (i.e. "pre-tanning agent”) is contacted with the collagen-containing material, e.g. the hide, before being contacted with a second tanning agent (i.e. "tanning agent").
  • pre-tanning agent a first tanning agent
  • the pre-tanning also enables the shaving of the leather before the second tanning agent is applied.
  • a tanning process may comprise or not a pre-tanning step.
  • a compound as defined herein may be used as a pre-tanning agent and/or tanning agent in a process comprising a pre-tanning step.
  • the pre-tanning agent and the tanning agent may be chosen from the group consisting of: polyphenolic extract for various vegetable, mainly gallnut, quebracho, oak, metal salt of chromium, iron, zirconium, titanium, aluminum, mainly with chloride and sulfate as counter ion, and synthetics chemicals like formol, glutaraldehyde, oxazolidine, zeolite, formol phenol (and derivate like cresol, phenol sulfonic acids) condensate, formol bisphenol (A, B, S and F) condensate, formol melamine condensate, and a mixture thereof.
  • a compound as defined herein may be used as a tanning agent in a tanning process not comprising a pre-tanning step.
  • the tanning process may in particular be a process for tanning a collagen-containing material, and more particularly for tanning a hide or a skin.
  • said collagen-containing material or said hide or skin, is treated (typically, contacted) with one or more compounds as defined herein, or a composition comprising the same.
  • collagen refers to naturally occurring collagens or modified collagens.
  • collagen as used herein also refers to collagens prepared using recombinant techniques.
  • the term collagen includes collagen, collagen fragments, collagen dispersion obtained from hide grinding and various purification steps (e.g. enzymatic or acidic hydrolysis), collagen fibers obtained through precipitation of dispersed or soluble collagen (e.g. salt, brine or ammoniac precipitation), collagen-like proteins, triple helical collagen, alpha chains, monomers, gelatin, trimers and combinations thereof.
  • Recombinant expression of collagen and collagen-like proteins is known in the art (see in particular EP 1,232,182 ; US 6,428,978 ; US 8,188,230 ).
  • the collagen can be a chemically-modified collagen, a truncated collagen, unmodified or post-translationally modified, or amino acid sequence-modified collagen.
  • the collagen can be plant-based collagen.
  • a collagen solution can be fibrillated into collagen fibrils.
  • collagen fibrils refer to nanofibers composed of tropocollagen or tropocollagen-like structures.
  • a recombinant collagen can comprise a collagen fragment of the amino acid sequence of a native collagen molecule capable of forming tropocollagen (trimeric collagen).
  • a recombinant collagen can also comprise a modified collagen or truncated collagen having an amino acid sequence at least 70, 80, 90, 95, 96, 97, 98, or 99% identical or similar to a native collagen amino acid sequence.
  • the collagen fragment can be a 50 kDa portion of a native collagen.
  • the collagen-containing material refers to a material comprising or consisting of collagen.
  • the collagen-containing material may be from any origin, in particular from an animal (e.g. goat, bovine such as calf, cow or cattle, ovine such as sheep or lamb, reptile such as crocodile or lizard, or fish such as trout or salmon).
  • said collagen-containing material is a hide or a skin.
  • the hide or skin may be from any animal, (e.g. goat, bovine such as calf, cow or cattle, ovine such as sheep or lamb, reptile such as crocodile or lizard, or fish such as trout or salmon).
  • the treating or contacting step may be carried out under classical conditions known to the skilled artisan.
  • the collagen-containing material in particular, said hide or skin
  • the collagen-containing material may be contacted with said one or more compounds as defined herein in an aqueous solution, optionally comprising further auxiliary agents such as, proteins, peptides, protein hydrosylates, polyamines, pH buffer, sodium chloride, sodium sulfate, sodium citrate, ammonium chloride, naphthalene sulfonic polymer, preservatives, or slippery agent.
  • the concentration of compound(s) as defined herein in the aqueous solution is typically comprised between 0.1 wt% and 40 wt%, preferably between 0.5% and 25%.
  • the pH of the aqueous solution may be within a range from 1 to 15, preferably from 7 to 11. Said pH may be adjusted by using a buffer, such as a carbonate or phosphate buffer.
  • the treating or contacting step may be carried out at a temperature comprised between 4 °C and 70 °C, preferably between 20 °C and 50 °C, more preferably between 30 °C and 40 °C.
  • the treating or contacting step may be carried out for a duration comprised between 1 hour and 90 hours, preferably between 15 hours and 50 hours.
  • the compound(s) as defined herein may be used in a tanning process in combination with other tanning agents, such as mineral, vegetal, organic or enzymatic tanning agents (e.g. polyphenolic extract for various vegetable, mainly gallnut, quebracho, oak, metal salt of chromium, iron, zirconium, titanium, aluminum, mainly with chloride and sulfate as counter ion, and synthetics chemicals like formol, glutaraldehyde, oxazolidine, zeolite, formol phenol (and derivate like cresol, phenol sulfonic acids) condensate, formol bisphenol (A, B, S and F) condensate, formol melamine condensate, and a mixture thereof).
  • the tanning step can be carried out in a tanning drum, a reactor or any other adapted device.
  • a compound as defined herein is contacted with an acid, such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, trifluoroacetic acid, methanesulfonic acid, benzenesulfonic acid or p- toluenesulfonic acid (preferably hydrochloric acid), before and/or during the contacting with the collagen-containing material.
  • Said acid is typically used in the form of an acid aqueous solution.
  • a process for tanning a collagen-containing material using a compound as defined herein can comprise:
  • Steps i), ii), and iii) can be carried out successively or simultaneously. Steps i), ii), and iii) can be carried out in any order, for instance in any one of the following orders:
  • a stabilizing salt may be added during the tanning process, for instance in the above steps (ii) or (iii), in order to prevent the degradation of the collagen-containing material which may occur under strong acid or basic conditions.
  • stabilizing salt include, but are not limited to, cation sulfates, cation hydrogen sulfates, cation naphthalene sulfonates, cation chloride, cation phosphate, cation citrate, cation succinate, cation tartrate, cation formate, cation acetate, cation propionate, cation sulfamate, or a mixture thereof, wherein the cation is preferably selected from the group consisting of sodium, potassium, calcium and magnesium.
  • a process for tanning a collagen-containing material using a compound as defined herein comprises:
  • Steps i'), ii'), and iii') can be carried out successively or simultaneously. Steps i'), ii'), and iii') can be carried out in any order, after step o'), for instance in any one of the following orders:
  • a stabilizing salt as defined above may be added during the tanning process, for instance in the above steps (ii') or (iii').
  • said iridoid, seco-iridoid, or derivative thereof is preferably chosen from aucubin, harpagide, catalpol, ajugol, geniposide, loganin, loganic acid, antirrhinoside, linarioside, feretoside, geniposidic acid, gardenoside, apodanthoside, desacetylasperulosidic acid, scandoside, methoxycinnamoyl scandoside methyl ester, demethyloleuropein, ligustroside, ligustrosidic acid, ligustaloside A, ligustaloside B, nuzhenide, horroxyloganin, oleuropein, hydroxyframoside A, hydroxyframoside B, sweroside, swertiamarin, gentiopicroside, amarogentin, and morroniside, preferably geniposide or gentiopi
  • compounds as defined herein have a low toxicity, in particular compared with the aglycone form of iridoids or seco-iridoids.
  • Compounds as defined herein advantageously have a median lethal dose (LD 50 ) higher than that of the corresponding aglycone form.
  • Compounds as defined herein may also allow to obtain a high-quality leather or leather substitute.
  • said leather or leather substitute may:
  • the shrinkage temperature may in particular be suitable to shave leather and to prepare the step of tanning (i.e. the step subsequent to the pre-tanning, if present in the tanning process).
  • the high-quality grain and leather surface may in particular be suitable for aniline finishing, and be characterized by a very low shrinking of the grain.
  • a leather or leather substitute refers typically to a material having similar properties as leather, and obtained by a tanning process applied to a substitute of an animal skin or hide.
  • Said leather or leather substitute can be used in the fashion, accessories, household's appliances and other furniture industries, and especially for manufacturing bags, shoes, watch straps, belts or wallets.
  • Another object of the present invention is a process for cross-linking collagen in a material comprising a step of contacting said material with a compound as defined herein.
  • Said material may in particular be a hide or skin.
  • Another object of the present invention is a compound as defined herein (e.g. compounds of formula (I), (1-2) or (1-1)) per se , with the proviso that said compound is not one of the following compounds (including any stereoisomer thereof):
  • said compound per se is a compound of formula (I) as defined herein, with the proviso that X is not a moiety of geniposide or loganin (or the aglycone form thereof).
  • R f 0.33 (SiO 2 , cyclohexane/AcOEt 65/35).
  • Potassium carbonate (680 g, 4.9 mmol, 3 eq), potassium ferricyanide (III) (2.7 g, 8.2 mmol, 5 eq), potassium osmate(VI) dihydrate (0.024 g, 0.06 mmol, 0.04 eq), and quinuclidine (0.015 g, 0.13 mmol, 0.08 eq) were suspended in THF/ H 2 O (2/1, 12 mL). After 5 min of stirring, a solution of 1 (866 g, 1.6 mmol) in THF (4 mL) was added to the reaction mixture. The dark suspension was vigorously stirred at room temperature overnight and sodium sulfite (1 g, 8.2 mmol, 5 eq) was introduced.
  • R f 0.25 (SiO 2 , cyclohexane/AcOEt 1/3).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Saccharide Compounds (AREA)
EP22306770.3A 2022-12-01 2022-12-01 Iridoid- oder seco-iridoidderivate und ihre verwendung in einem gerbverfahren Pending EP4379068A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22306770.3A EP4379068A1 (de) 2022-12-01 2022-12-01 Iridoid- oder seco-iridoidderivate und ihre verwendung in einem gerbverfahren

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22306770.3A EP4379068A1 (de) 2022-12-01 2022-12-01 Iridoid- oder seco-iridoidderivate und ihre verwendung in einem gerbverfahren

Publications (1)

Publication Number Publication Date
EP4379068A1 true EP4379068A1 (de) 2024-06-05

Family

ID=84537488

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22306770.3A Pending EP4379068A1 (de) 2022-12-01 2022-12-01 Iridoid- oder seco-iridoidderivate und ihre verwendung in einem gerbverfahren

Country Status (1)

Country Link
EP (1) EP4379068A1 (de)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428978B1 (en) 1998-05-08 2002-08-06 Cohesion Technologies, Inc. Methods for the production of gelatin and full-length triple helical collagen in recombinant cells
EP1232182A2 (de) 1999-11-12 2002-08-21 Fibrogen, Inc. Tierische kollagene und gelatine
WO2009065915A1 (de) 2007-11-23 2009-05-28 N-Zyme Biotec Gmbh Mittel und verfahren zur gerbung von häuten und fellen
US8188230B2 (en) 1997-12-24 2012-05-29 Fuji Film Manufacturing Europe B.V. Method for recombinant microorganism expression and isolation of collagen-like polypeptides
CN102925508A (zh) * 2011-08-10 2013-02-13 浙江毕尔锐思生物技术股份有限公司 一种制备环烯醚萜甙元的方法
US20170080040A1 (en) * 2014-05-15 2017-03-23 Livio Pesle Decoction of olive leaves
WO2018025210A1 (en) * 2016-08-03 2018-02-08 Tannow S.R.L. Use of olive mill waste waters in the leather tanning industry
US20190002893A1 (en) 2017-06-29 2019-01-03 Modern Meadow, Inc. Yeast strains and methods for producing collagen
US20190040400A1 (en) 2017-07-31 2019-02-07 Modern Meadow, Inc. Yeast strains and methods for controlling hydroxylation of recombinant collagen
US20190092838A1 (en) 2017-09-22 2019-03-28 Modern Meadow, Inc. Recombinant yeast strains

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188230B2 (en) 1997-12-24 2012-05-29 Fuji Film Manufacturing Europe B.V. Method for recombinant microorganism expression and isolation of collagen-like polypeptides
US6428978B1 (en) 1998-05-08 2002-08-06 Cohesion Technologies, Inc. Methods for the production of gelatin and full-length triple helical collagen in recombinant cells
EP1232182A2 (de) 1999-11-12 2002-08-21 Fibrogen, Inc. Tierische kollagene und gelatine
WO2009065915A1 (de) 2007-11-23 2009-05-28 N-Zyme Biotec Gmbh Mittel und verfahren zur gerbung von häuten und fellen
CN102925508A (zh) * 2011-08-10 2013-02-13 浙江毕尔锐思生物技术股份有限公司 一种制备环烯醚萜甙元的方法
US20170080040A1 (en) * 2014-05-15 2017-03-23 Livio Pesle Decoction of olive leaves
WO2018025210A1 (en) * 2016-08-03 2018-02-08 Tannow S.R.L. Use of olive mill waste waters in the leather tanning industry
US20190002893A1 (en) 2017-06-29 2019-01-03 Modern Meadow, Inc. Yeast strains and methods for producing collagen
US20190040400A1 (en) 2017-07-31 2019-02-07 Modern Meadow, Inc. Yeast strains and methods for controlling hydroxylation of recombinant collagen
US20190092838A1 (en) 2017-09-22 2019-03-28 Modern Meadow, Inc. Recombinant yeast strains
US20190093116A1 (en) 2017-09-22 2019-03-28 Modern Meadow, Inc. Recombinant yeast strains

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DING ET AL., JALCA, vol. 103, 2008, pages 377
TAYLOR ET AL., JALCA, vol. 104, 2009, pages 79
ZHANG ET AL., JALCA, vol. 106, 2011, pages 121

Similar Documents

Publication Publication Date Title
EP4379068A1 (de) Iridoid- oder seco-iridoidderivate und ihre verwendung in einem gerbverfahren
FULLMER et al. The staining of collagen with elastic tissue stains
DE19737327A1 (de) Hydroxyzimtsäureamide hydroxysubstituierter aromatischer Amine
EP3404033B1 (de) C-glucoside-derivat mit kondensiertem phenylring oder pharmazeutisch unbedenklichem salz davon, verfahren zur herstellung davon und pharmazeutische zusammensetzung damit
EP1801099B1 (de) Dithiolmischungen zum Entfernen von Hornsubstanzen aus Häuten
DE2808111A1 (de) Neue dipeptidderivate und deren verwendung zur messung der enzymatischen aktivitaet
EP4379067A1 (de) Iridoidderivate und ihre verwendung in einem gerbverfahren
KR960023088A (ko) 모피의 예비탄닝 또는 가죽의 재탄닝용 수성 조성물
DE2602314C3 (de) Verfahren zur Herstellung von reinem Diosmin
Tsutsumi et al. Reaction of syringylglycerol-β-syringyl ether type of lignin model compounds in alkaline medium
EP0008032B1 (de) Kondensationsprodukte aus Terphenylsulfonsäuren, Naphthalinsulfonsäuren, Bis-(4-hydroxyphenyl)-sulfon und Formaldehyd und ihre Verwendung als Gerbstoffe
Käsbeck et al. Convenient Syntheses of 2, 3, 4, 6‐Tetra‐O‐Alkylated d‐Glucose and d‐Galactose
US1198040A (en) Impregnated wood and process of making the same.
EP0554216A1 (de) Verfahren zum Pickeln und Vorgerben von Hautblössen
US2733977A (en) Process of tanning with salt of ampho-
DE19651040C2 (de) Verfahren zur Herstellung von 2-Amino-5-alkyl-phenolen
DE833190C (de) Verfahren zur Herstellung von AEthern
US3288812A (en) Diol derivative of cyclooctane
SU1595913A1 (ru) Способ выработки кож
US2164101A (en) Treating gut
FR2777281A1 (fr) Procede de synthese du d-laminaribiose
US3404151A (en) Novel hydroxyl amine triazine compounds and process for producing the same
Diolez et al. Chemistry of bacterial endotoxins. Part 3. Reactions of oxazolines derived from 1, 3, 4, 6-tetra-O-acetyl-2-[(3 R)-3-hydroxytetradecanamido]-β-D-glucopyranose
US1375976A (en) Manufacture of substances precipitating glue
AT205962B (de) Verfahren zur Herstellung von neuen ungesättigten aliphatischen Amino-diolen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR